Despite the Phase 3 failure of efzofitimod to significantly reduce steroid dependence in pulmonary sarcoidosis, aTyr Pharma intends to engage regulatory authorities to explore possible pathways forward. Efzofitimod, a tRNA synthetase-derived immunomodulatory candidate, remains under evaluation in additional clinical settings including systemic sclerosis-related interstitial lung disease. Following the setback, the company reassures stakeholders that its strategic focus and dialogue with the FDA will determine next steps to maximize therapeutic potential.